Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
A Suvannasankha, N Bahlis, S Trudel, K Weisel… - Cancer, 2024 - Wiley Online Library
Background Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in
relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that …
relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that …